Co-director of WHRI/Professor of Immunopharmacology
Mauro has published over 280 papers, with >11,000 citations and an H Factor of 60 (Google Scholar).
After BSc in Pharmaceutical Chemistry (University in Florence, 1985) and a MSc in Pharmacology and Toxicology (1988), Mauro started his career at the Sclavo Research Centre under the leadership of Prof Luca Parente. In 1991 he joined Prof Rod Flower at the William Harvey Research Institute, and in 1996 he gained his PhD (LON).
Mauro career has been shaped by fellowships from the Arthritis Research Campaign, a post-doctoral one (1997-2002) followed by a senior fellowship (2002-2007). In 2001 Mauro gained his personal chair by Queen Mary University of London; in 2011 he took the Leadership of the Centre for Biochemical Pharmacology, with Prof Marelli-Berg as Deputy. Since 2006 he acts as Deputy Director of the William Harvey Research Institute, a role he still carries on.
Mauro is Fellow of the British Pharmacological Society (FBPharmacolS, 2004), of the Academia Europea (2010) and of the Society of Biology (2012).
Summary of Research
We pioneered the concept that acute inflammation resolves, naturally, by the engagement of endogenous mediators that activate a series of non-redundant processes (inhibition of immune cell trafficking, efferocytosis, tissue repair) typical of what we now call the Resolution of Inflammation. When resolution is malfunctioning it contributes to chronic inflammatory diseases. We study the pathophysiology of some pro-resolving pathways (eg. Annexin A1 and its peptides, Glucocorticoids+calcitonin, Melanocortins, omega-3 derivatives) and aim to identify novel receptors amenable for the development of innovative anti-inflammatory therapeutics. A current focus is on pro-resolving GPCRs, such as FPR2/ALX and MC3, establishing their expression in disease; homo/heterodimerization and discovering novel biological functions.
Molecular pharmacology and cell biology protocols are complemented by integrated biology models (intravital microscopy for vascular responses, peritonitis, paw oedema, airpouch) including models of disease (arthritis, myocardial infarct and stroke). Each project is different in its practicality since it is the scientific question that drives the experimental protocols to be applied or developed, hence creativity is a must!
We are acutely aware of the importance to assess the relevance of our research in clinical settings, as this would accelerate the development of innovative therapeutics modelled on resolution; currently the focus is on rheumatology, cardiac surgery, sepsis and vasculitides.
Expression of the pro-resolving receptor FPR2 (a GPCR that transduces the actions of AnnexinA1 and Lipxin A4) as revealed by Green Florescence Protein detection, using a unique mouse colony engineered with this reporter under FPR2 promoter (funded by The Wellcome Trust).
Microcapsules (MC; green) can be used to deliver biologically active molecules to modulate the interaction between human leukocytes and the endothelium. (Collaboration with Prof Sukhorukov, QMUL).
Members of the Group
Research staff: Lucy Norling; T Gobbetti; M Kaneva; T Montero-Melendez; B Gittens; Dianne Cooper; Hefin R Jones, Patricia Souza; .
Visiting Scientists: AP Piovezan; F Mafra de Lima.
For a full list of publist publications click here
Nadkarni S, Dalli J, Hollywood J, Mason JC, Dasgupta B, Perretti M.
Investigational analysis reveals a potential role for neutrophils in giant-cell
arteritis disease progression. Circ Res. 2014 Jan 17;114(2):242-8. doi:
10.1161/CIRCRESAHA.114.301374. Epub 2013 Oct 24. PubMed PMID: 24158630.
Cooray SN, Gobbetti T, Montero-Melendez T, McArthur S, Thompson D, Clark AJ, Flower RJ, Perretti M. Ligand-specific conformational change of the G-protein-coupled receptor ALX/FPR2 determines proresolving functional responses. Proc Natl Acad Sci U S A. 2013 Nov 5;110(45):18232-7. doi:10.1073/pnas.1308253110. PMID: 24108355
Brancaleone V, Gobbetti T, Cenac N, le Faouder P, Colom B, Flower RJ,
Vergnolle N, Nourshargh S, Perretti M. A vasculo-protective circuit centered on
lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 operative in murine
microcirculation. Blood. 2013 Jul 25;122(4):608-17. doi:
10.1182/blood-2013-04-496661. Epub 2013 Jun 3. PubMed PMID: 23733341; PubMed Central PMCID: PMC3724196
Patel HB, Kornerup KN, Sampaio AL, D'Acquisto F, Seed MP, Girol AP, Gray M,
Pitzalis C, Oliani SM, Perretti M. The impact of endogenous annexin A1 on
glucocorticoid control of inflammatory arthritis. Ann Rheum Dis. 2012
Nov;71(11):1872-80. doi: 10.1136/annrheumdis-2011-201180. Epub 2012 May 5. PubMed PMID: 22562975; PubMed Central PMCID: PMC3440300.
Dalli J, Norling LV, Renshaw D, Cooper D, Leung KY, Perretti M. Annexin 1
mediates the rapid anti-inflammatory effects of neutrophil-derived
microparticles. Blood. 2008 Sep 15;112(6):2512-9. doi:
10.1182/blood-2008-02-140533. Epub 2008 Jul 1. PubMed PMID: 18594025.
Internal: Dr Michele Bombardieri; Dr FulvioD’Acquisto; Prof Federica Marelli-Berg; Dr Charles Hinds; Prof Sussan Nourshargh; Prof Cos Pitzalis; Dr Egle Solito; Prof Gleb Sukhorukov; Prof Chris Thiemermann;
External: B Dasgupta (Southend University Hospital); S Farsky (USP, Sao Paulo, Brazil); J Mason (Imperial College); A Nusrat (Emory University, Atlanta); SM Oliani (UNESP, Sao José do Rio Preto, Brazil); C Reutelingsperger (Maastricht University); CN Serhan (Harvard Medical School, Boston); MM Teixeira (UNMG, Belo Horizonte, Brazil); N Vergnolle (INSERM, Toulouse); JL Wallace (McMaster University, Hamilton); V Witko-Sarsat (Cochin Hopital, Paris);
Industrial: N Mehta; A Consalvo (Unigene Corporation); T Jonassen (SynAct Pharma ApS, Aarhus); A Moore (UCB Celltech, Slough); D Taylor; A Kamal (MRC Technology, London).
Mauro Perretti, PhD, FBPharmacolS, FSB
Professor of Immunopharmacology
Co-Director William Harvey Research Institute
Barts and The London School of Medicine
Queen Mary University of London
London, EC1M 6BQ
T: +44 (0) 20 77882 8782
PA: Miss Silvia Ayguade